Skip to main content
. 2020 Jun 16;13(9):1210–1223. doi: 10.1016/j.jiph.2020.06.016

Fig. 9.

Fig. 9

Substrate binding cleft of SARS-CoV-2 Mpro harboring the docked inhibitors. Top three docked inhibitors. (A) Tipranavir, (B) Lopinavir–Ritonavir, and (C) Raltegravir occupy the active site region with independent confirmation as the originally (D) bound α-ketoamide 13b ligand in the co-crystallized structure (PDB ID: 6Y2F).